Cervical Cancer Treatment Market Size, Share, and Industry Analysis By Therapy (Chemotherapy, Targeted Therapy, Immunotherapy, and Others), By Cancer Type (Squamous Cell Carcinoma and Adenocarcinoma), By Route of Administration (Oral and Parenteral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2024-2032

Cervical cancer originates in the cells of the cervix, the lower, narrow part of the uterus that joins to the vagina. It typically develops slowly over time, starting with precancerous changes known as dysplasia, where abnormal cells begin to appear in the cervical tissue. If left untreated, these abnormal cells can progress to become cancerous and spread deeper into the cervix and surrounding areas. It is typically caused by the human papillomavirus (HPV) infection, which can be detected through regular Pap smear tests.

There are two major types of cervical cancer, which includes the squamous cell carcinoma and adenocarcinoma. Squamous cell carcinoma is the most common type of cervical cancer, accounting for about 70-90% of cases.

The market is comprised of the drugs used in the cervical cancer management. The increasing prevalence of cervical cancers globally and the increasing R&D investments by major players for new drug development are the key factors anticipated to drive the market.

• According to WHO, in 2022, cervical cancer ranked as the fourth most common cancer among women worldwide, with approximately 660,000 new cases and around 350,000 fatalities.

Moreover, the market for cervical cancer treatment is expected to grow owing to the increasing prevalence of HPV infections, improved screening and early detection methods, and advancements in treatment options.

The COVID-19 pandemic had a significant impact on the cervical cancer treatment market. The lockdown caused disruptions in healthcare services, including regular doctor visits and treatment, which affected the treatment and management of cervical cancer. However, in 2021, the lockdown relaxation facilitated doctor visits, diagnostics & treatment, and the market witnessed growth.

The increasing incidence of cervical cancer diagnosis and the growing number of drug candidates in the pipeline is anticipated to propel market growth in the near future. Furthermore, the rising governmental initiatives to increase cervical cancer awareness among the population is expected to increase the rate of diagnosis, boosting treatment demand over the forecast period.

Key Insights

• Prevalence of Cervical Cancer, by Key Countries/ Region, 2023


• Pipeline Analysis


• Overview: Regulatory and Reimbursement Scenario, By Key Countries/Regions


• Key Industry Developments: New Product Launches, Acquisitions, Mergers, Partnerships, and Others


• Impact of COVID-19 on the Market

Segmentation

Analysis by Therapy

Based on therapy, the market is classified into chemotherapy drugs, targeted therapy drugs, and immunotherapy drugs. The chemotherapy drugs segment holds a significant market share as they are widely used in the treatment of cervical cancer. The wider availability and cost-effectiveness of chemotherapy drugs compared to other drugs is increasing the penetration of these drugs across the globe. 

The targeted therapy segment is expected to witness significant growth over the coming years due to its higher efficacy and fewer side effects compared to traditional chemotherapy. Moreover, the extensive clinical investigations to use monoclonal antibodies as a target therapy and the rising number of pipeline drugs is anticipated to boost the segment growth in the near future.

Regional Analysis

North America accounted for the largest revenue share in 2023. The region is expected to dominate the cervical cancer treatment market due to the high prevalence of cervical cancers in the region, along with the presence of major players in the market. Furthermore, an increase in the drug discovery initiatives among key industry players for new formulations and promising drug candidates is expected to enhance the regional market over the coming years. Moreover, strategic acquisitions by key players to enhance the portfolio and clinical trial initiatives expected to be a potential factor for market growth over the coming years.

• For instance, in December 2023, Pfizer Inc. acquired Seagen Inc., a global biotechnology company that developed TIVDAK (tisotumab vedotin) for the treatment of cervical cancer.

The Asia Pacific region is expected to witness faster growth prospects in the cervical cancer treatment market due to the growing awareness of cervical cancer and the rising number of cervical cancer prevalence. Moreover, the rising R&D investments for the discovery and development of cancer drugs in the region are expected to propel the market growth over projected years.

Key Players Covered

The report includes the profiles of key players such as Pfizer Inc, Novartis AG, Amgen Inc., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche Ltd, and GL Pharma.

Key Industry Developments

• In February 2024, Pfizer Inc. and Genmab A/S announced that the European Medicines Agency (EMA) validated for review the marketing authorization application (MAA) of tisotumab vedotin for the treatment of recurrent or metastatic cervical cancer. It is an antibody-drug conjugate (ADC) developed by both companies.


• In January 2024, Merck & Co., Inc., received the U.S. FDA approval for Keytruda to treat patients with stage 3 to 4a cervical cancer. It is a PD-1 drug used in combination with chemoradiotherapy.


• In June 2023, Nykode Therapeutics collaborated with F. Hoffmann-La Roche Ltd for a clinical trial in advanced cervical cancer. This trial would investigate Nykode Therapeutics’s lead candidate VB10.16 in combination with F. Hoffmann-La Roche Ltd immunotherapy drug Tecentriq (atezolizumab).